AHL Partners’s Blueprint Medicines BPMC Stock Holding History

AHL Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-6,003	Closed	-$419K	–	1264
2017 Q3	$419K	Buy	+6,003	New	+$321K	0.01%	1093

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

AHL Partners's BPMC Position: Q4 2017 in Review

AHL Partners sold out of Blueprint Medicines (BPMC) in Q4 2017, closing a stake of 6,003 shares — an estimated $419K sold.

AHL Partners first reported a position in BPMC in Q3 2017 and held it in 1 quarter. The position peaked at $419K in Q3 2017. 170 funds tracked by Wall St. Rank hold BPMC as of Q4 2017.

AHL Partners reported no remaining Blueprint Medicines position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 6,003 Blueprint Medicines shares in Q4 2017, an estimated $419K.
AHL Partners first reported a position in Blueprint Medicines in Q3 2017 and held it in 1 quarter.
AHL Partners's Blueprint Medicines position peaked at $419K in Q3 2017.
170 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.